Vesencumab  (Synonyms: 维森库单抗; MNRP-1685A)

Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

NRP1/VEGF165R/CD34

Vesencumab (50 μg/mL, 6 days) 通过抑制 EGFR 和 PDGFRα 的活化来抑制 MAPK 信号通路，从而抑制 SUM159 和 Hs578T 肿瘤细胞的球体形成^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Vesencumab (10 mg/kg, ip, twice a week for 7 weeks) 在小鼠 SUM159 原位异种移植模型中表现出抗肿瘤作用^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

8829  [NCBI]

O14786

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.262 kDa

1205533-60-3

液体

Colorless to light yellow

维森库单抗；维森单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Neuropilin-1 Protein, Human (His) can bind Vesencumab. The EC₅₀ for this effect is 5.571 ng/mL.
• 
  Loaded Vesencumab on AHC2 biosensor, can bind Glycoprotein/G Protein, HRSV (95% Homology, HEK293, His, HY-P75814) with an affinity constant of 1.372E-09 M as determined in BLI assay.

• [1]. Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced? Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.

  [2]. Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362.  [Content Brief]